Wells Fargo’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.3M Buy
127,134
+7,796
+7% +$1.44M ﹤0.01% 1414
2025
Q4
$21M Sell
119,338
-56,926
-32% -$9.3M ﹤0.01% 1464
2025
Q3
$24.7M Buy
176,264
+10,302
+6% +$1.39M ﹤0.01% 1346
2025
Q2
$20.8M Buy
165,962
+11,477
+7% +$1.43M ﹤0.01% 1378
2025
Q1
$21.1M Buy
154,485
+43,442
+39% +$6.21M ﹤0.01% 1296
2024
Q4
$17M Sell
111,043
-95,427
-46% -$16.1M ﹤0.01% 1463
2024
Q3
$40M Sell
206,470
-41,290
-17% -$8.64M 0.01% 905
2024
Q2
$57.4M Buy
247,760
+26,684
+12% +$5.8M 0.01% 710
2024
Q1
$47.7M Sell
221,076
-10,375
-4% -$2.43M 0.01% 781
2023
Q4
$59.9M Buy
231,451
+16,778
+8% +$4.12M 0.02% 660
2023
Q3
$55.2M Sell
214,673
-35,155
-14% -$9.4M 0.02% 640
2023
Q2
$71.2M Sell
249,828
-5,194
-2% -$1.55M 0.02% 578
2023
Q1
$70.9M Sell
255,022
-11,086
-4% -$3.07M 0.02% 555
2022
Q4
$73.7M Sell
266,108
-52,870
-17% -$14.9M 0.02% 530
2022
Q3
$85.2M Sell
318,978
-40,101
-11% -$8.52M 0.03% 443
2022
Q2
$73.2M Sell
359,079
-80,651
-18% -$16.5M 0.02% 519
2022
Q1
$92.6M Buy
439,730
+38,751
+10% +$8.43M 0.02% 516
2021
Q4
$96.2M Sell
400,979
-172,597
-30% -$44.4M 0.02% 505
2021
Q3
$162M Buy
573,576
+23,940
+4% +$7.85M 0.04% 464
2021
Q2
$190M Sell
549,636
-31,100
-5% -$9.42M 0.04% 415
2021
Q1
$162M Sell
580,736
-17,943
-3% -$4.84M 0.04% 459
2020
Q4
$147M Sell
598,679
-153,694
-20% -$39.6M 0.04% 480
2020
Q3
$213M Buy
752,373
+7,649
+1% +$2.13M 0.06% 315
2020
Q2
$199M Buy
744,724
+42,187
+6% +$12.7M 0.06% 314
2020
Q1
$222M Sell
702,537
-131,668
-16% -$40M 0.08% 247
2019
Q4
$248M Sell
834,205
-13,213
-2% -$3.67M 0.07% 287
2019
Q3
$197M Sell
847,418
-2,838
-0.3% -$661K 0.06% 349
2019
Q2
$199M Sell
850,256
-101,332
-11% -$23.4M 0.06% 334
2019
Q1
$225M Sell
951,588
-104,981
-10% -$33.1M 0.07% 286
2018
Q4
$318M Buy
1,056,569
+50,469
+5% +$16.1M 0.11% 191
2018
Q3
$355M Sell
1,006,100
-42,527
-4% -$14.6M 0.1% 197
2018
Q2
$304M Buy
1,048,627
+33,848
+3% +$9.52M 0.09% 226
2018
Q1
$278M Sell
1,014,779
-135,698
-12% -$42.1M 0.08% 249
2017
Q4
$367M Buy
1,150,477
+174,485
+18% +$56M 0.11% 190
2017
Q3
$306M Sell
975,992
-212,583
-18% -$62.9M 0.09% 215
2017
Q2
$323M Buy
1,188,575
+43,079
+4% +$11.4M 0.1% 201
2017
Q1
$313M Buy
1,145,496
+182,345
+19% +$51.6M 0.1% 198
2016
Q4
$273M Sell
963,151
-122,736
-11% -$36.4M 0.1% 219
2016
Q3
$340M Buy
1,085,887
+11,297
+1% +$3.35M 0.13% 177
2016
Q2
$260M Buy
1,074,590
+239,557
+29% +$63.1M 0.1% 215
2016
Q1
$217M Buy
835,033
+55,808
+7% +$14.7M 0.09% 260
2015
Q4
$239M Sell
779,225
-502,027
-39% -$144M 0.09% 246
2015
Q3
$374M Sell
1,281,252
-948,108
-43% -$313M 0.16% 153
2015
Q2
$901M Sell
2,229,360
-178,830
-7% -$71.8M 0.35% 48
2015
Q1
$1.02B Sell
2,408,190
-303,123
-11% -$119M 0.4% 33
2014
Q4
$920M Buy
2,711,313
+18,842
+0.7% +$6.1M 0.36% 44
2014
Q3
$891M Buy
2,692,471
+186,419
+7% +$61.5M 0.37% 39
2014
Q2
$790M Buy
2,506,052
+96,081
+4% +$28.9M 0.33% 52
2014
Q1
$737M Buy
2,409,971
+275,909
+13% +$87.6M 0.31% 56
2013
Q4
$597M Buy
2,134,062
+154,502
+8% +$40M 0.26% 82
2013
Q3
$477M Buy
1,979,560
+46,785
+2% +$10.5M 0.23% 101
2013
Q2
$416M Buy
+1,932,775
New +$413M 0.22% 105

Other funds holding BIIB

Wells Fargo's BIIB Position: Q1 2026 in Review

Wells Fargo increased its Biogen (BIIB) stake by 6.5% in Q1 2026, buying an estimated $1.44M and bringing the position to 127,134 shares worth $23.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

Wells Fargo first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.02B in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Wells Fargo held 127,134 shares of Biogen worth $23.3M as of Q1 2026.
  • Wells Fargo bought 7,796 Biogen shares in Q1 2026, an estimated $1.44M.
  • Biogen made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1414 holding.
  • Wells Fargo first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Biogen position peaked at $1.02B in Q1 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.